Area of research
Physiology · Surgery
Research interest
Research interests include Medicine, Dupilumab, Asthma, Lung function, Exacerbation, and Mucus.
Current Smoker: A Clinical Chronic Obstructive Pulmonary Disease Phenotype Affecting Disease Progression and Response to Therapy
Effect of dupilumab on mucus burden in patients with moderate-to-severe asthma: the VESTIGE trial
Transient early blood eosinophil increases do not affect dupilumab’s long-term efficacy in patients with moderate-to-severe asthma
Le dupilumab réduit l’obstruction et le volume du mucus : essai de phase 4 VESTIGE
The interleukin-4/interleukin-13 pathway in type 2 inflammation in chronic rhinosinusitis with nasal polyps
Biomarkers Associated with Lung Function Decline and Dupilumab Response in Patients with Asthma
The Emerging Role of Alarmin-Targeting Biologics in the Treatment of Patients With COPD
Real-world effectiveness of dupilumab versus benralizumab and mepolizumab
Evaluating the Effect of Dupilumab on Type 2 Airway Inflammation and Mucus Plugging in Patients with Uncontrolled Moderate-To-Severe Asthma: the VESTIGE Trial
Dupilumab sustains lung function improvements in patients with moderate-to-severe asthma
Long-Term Dupilumab Efficacy on Severe Exacerbations and Lung Function in Patients with Type 2 Asthma
Dupilumab reduces mucus plugging and volume: phase 4 VESTIGE trial
Impact of Early Transient Increase in Eosinophil Count on the Long-term Efficacy of Dupilumab in Patients With Moderate-to-Severe Asthma: Liberty Asthma Traverse
Effect of Dupilumab Treatment on Mucus Plugging and Mucus Volume in Type 2 Asthma: The Phase 4 VESTIGE Trial
Early treatment response to dupilumab on airway inflammation, airway dynamics, and mucus plugging in VESTIGE
Évaluation de l’effet du dupilumab sur l’inflammation de type 2 des voies respiratoires et le bouchon de mucus chez les patients souffrant d’asthme modéré à sévère non contrôlé : l’essai VESTIGE
Dupilumab-treated patients with moderate-to-severe asthma are more likely to meet clinical remission criteria: results from the VESTIGE trial
Impact of early transient increase in eosinophils in patients with moderate-to-severe asthma on the long-term efficacy of dupilumab in TRAVERSE
Impact of Dupilumab on Sinonasal Symptoms and Outcomes in Severe Chronic Rhinosinusitis With Nasal Polyps
Real-world effectiveness of dupilumab in patients with asthma
Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils
Dupilumab sustains efficacy in patients with moderate‐to‐severe type 2 asthma regardless of inhaled corticosteroids dose
Dupilumab Reduces Exacerbations And Improves Lung Function Regardless Of Prior Asthma Exacerbation Status: LIBERTY ASTHMA TRAVERSE Open-Label Extension Study
La FeNO, un marqueur pronostique et prédictif potentiel de déclin de la fonction respiratoire chez des patients atteints d’asthme modéré à sévère non contrôlé : LIBERTY ASTHMA QUEST
Dupilumab improves exacerbations and lung function irrespective of prior asthma exacerbations: TRAVERSE
Disease Burden and Unmet Need in Eosinophilic Esophagitis
Dupilumab Efficacy in Patients With Uncontrolled or Oral Corticosteroid–Dependent Allergic and Nonallergic Asthma
Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction
Dupilumab efficacy in subgroups of type 2 asthma with high-dose inhaled corticosteroids at baseline
Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate‐to‐severe type 2 asthma
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Physiology · Surgery →